Additionally, owing to the high cost of renal replacement therapy, results from clinical trials indicate that SGLT2 inhibitors are cost-effective in patients with CKD,30,31 with and without T2DM.32 This evidence concerns the gene SLC5A2 and chronic kidney disease.